Dr. Cohen received his M.D. from the University of Pennsylvania School of Medicine. He completed internal medicine residency training at the Massachusetts General Hospital and then obtained fellowship training in adult hematology and medical oncology at the Dana-Farber/Brigham and Women’s and Massachusetts General Hospital combined fellowship program. Following fellowship, he became an Instructor at the MGH where his research focused on the role of angiogenic progenitor cells in tumor vascular biology. He was then recruited to the University of Chicago in 2007 as an Assistant Professor of Medicine. He is currently an Associate Professor of Medicine at the University of Chicago. He serves as Program Director of the Adult Hematology/Oncology Fellowship Program and is Program Leader of Classical Hematology. He is also Director of the University of Chicago HHT Center of Excellence. Clinically he cares for patients with HHT as well as disorders of thrombosis and hemostasis.
A Pilot Study Omitting Radiation in the Treatment of Children with Newly Diagnosed Wnt-Activated Medulloblastoma.
A Pilot Study Omitting Radiation in the Treatment of Children with Newly Diagnosed Wnt-Activated Medulloblastoma. Clin Cancer Res. 2023 12 15; 29(24):5031-5037.
PMID: 37498309
Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908.
Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908. Neuro Oncol. 2023 08 03; 25(8):1530-1545.
PMID: 36808285
Comparative effectiveness of the sars-CoV-2 vaccines during delta dominance.
Comparative effectiveness of the sars-CoV-2 vaccines during delta dominance. Heliyon. 2023 May; 9(5):e16006.
PMID: 37163164
Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT Trial.
Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT Trial. Clin Infect Dis. 2023 02 08; 76(3):e1-e9.
PMID: 36124697
Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study.
Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study. J Clin Oncol. 2023 04 01; 41(10):1921-1932.
PMID: 36548930
Comparison of Care Quality Metrics in 2-Sided Risk Medicare Advantage vs Fee-for-Service Medicare Programs.
Comparison of Care Quality Metrics in 2-Sided Risk Medicare Advantage vs Fee-for-Service Medicare Programs. JAMA Netw Open. 2022 12 01; 5(12):e2246064.
PMID: 36508218
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N Engl J Med. 2022 08 18; 387(7):599-610.
PMID: 36070710
Association of Progestogens and Venous Thromboembolism Among Women of Reproductive Age.
Association of Progestogens and Venous Thromboembolism Among Women of Reproductive Age. Obstet Gynecol. 2022 09 01; 140(3):477-487.
PMID: 35926206
A data-based foundation for managing hypertension services.
A data-based foundation for managing hypertension services. Am J Manag Care. 2022 08 01; 28(8):e282-e288.
PMID: 35981128
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica. 2022 07 01; 107(7):1608-1618.
PMID: 34320785